This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamidedexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾ 65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with carfilzomib until progression/intolerance. The phase 1 portion used a 3+3 dose-escalation scheme to determine the maximum tolerated dose of weekly carfilzomib: 12 patients received wKCyd with carfilzomib doses of 45, 56 and 70 mg/m 2 . The recommended phase 2 dose was established at 70 mg/m 2 and 54 patients (phase 1 and 2) received weekly carfilzomib 70 mg/m 2 : 85% of them achieved ⩾ partial response (PR), 66% ⩾ very good PR, 30% ⩾ near-complete response (CR) and 15% CR. Responses improved in 40 patients who started maintenance: 98% achieved ⩾ PR, including 29% CR and 10% stringent CR. After a median follow-up of 18 months, the 2-year progression-free survival and overall survival rates were 53.2% and 81%, respectively. The most frequent grade 3-5 toxicities were neutropenia (22%) and cardiopulmonary adverse events (9%). This is the first study of weekly carfilzomib plus an alkylating agent in elderly patients with NDMM. wKCyd was effective, with an acceptable risk/benefit ratio, and thus can be a valid option in this setting.
INTRODUCTION
In the last decade, the increased use of novel agents as initial therapy of multiple myeloma (MM) significantly improved overall survival (OS) in patients ineligible for autologous transplantation. 1 In Europe, bortezomib-melphalan-prednisone (VMP) and melphalanprednisone-thalidomide combinations are considered standards of care in elderly patients ineligible for autologous stem cell transplantation. 2, 3 Dose-limiting haematological toxicity from melphalan and peripheral neuropathy from bortezomib or thalidomide limit their optimal use. 4, 5 Better tolerated alkylating agents, such as cyclophosphamide, which lack the cumulative haematological toxicity of melphalan, have been used successfully in combination with dexamethasone and either thalidomide 6 or bortezomib 7 in elderly newly diagnosed MM (NDMM) patients. Recently, based on the results of MM020 trial, a new standard of care with no alkylating agent has been introduced for the treatment of elderly patients with NDMM. Indeed, that study prospectively compared outcomes of melphalan-prednisone-thalidomide versus lenalidomide and low-dose dexamethasone, and found that treatment with lenalidomide and dexamethasone until disease progression improved progression-free survival (PFS) and OS compared with melphalan-prednisone-thalidomide. 8 Carfilzomib, a novel and selective proteasome inhibitor, received accelerated approval in the United States in 2012 for the treatment of patients with relapsed and refractory MM. It is approved in the United States and Europe when used in combination with dexamethasone or lenalidomide plus dexamethasone for patients with relapsed MM (one to three prior lines of therapy). 9 Under the initial approvals, carfilzomib is administered as a 10 min infusion on a twice-weekly dosing schedule, with a starting dose of 20 mg/m 2 on cycle 1 days 1 and 2, and stepped up to a target dose of 27 mg/m 2 thereafter. Prolonged infusion over 30 min has been assessed in clinical studies showing that higher carfilzomib doses (56 mg/m 2 ) in combination with dexamethasone were safe and effective. 10, 11 These findings were confirmed with the results of the randomized phase 3 ENDEAVOR trial (RandomizEd, opeN Label, Phase 3 Study of carfilzomib plus DExamethAsone Vs bortezomib plus DexamethasOne in Patients With Relapsed Multiple Myeloma; NCT01568866) comparing carfilzomib plus dexamethasone versus bortezomib plus dexamethasone in relapsed/refractory MM, which supported the approval of twice-weekly carfilzomib (at 56 mg/m 2 ) with dexamethasone for patients with relapsed MM.
Twice-weekly intravenous administration of anti-myeloma therapy can be burdensome for patients, especially for those who are elderly, suffer from myeloma-related symptoms, or who live far from the clinic. Based on results from studies showing that once-weekly bortezomib has similar efficacy and a better safety profile compared with the conventional twice-weekly administration, 13 and to follow up on the CHAMPION-1 study evaluating weekly carfilzomib plus dexamethasone in the relapse setting, 14 we aimed to evaluate efficacy and tolerability of onceweekly carfilzomib plus cyclophosphamide and dexamethasone (wKCyd) in NDMM elderly patients. We previously showed that treatment with twice-weekly carfilzomib in combination with cyclophosphamide-dexamethasone (KCyd) was highly effective and well tolerated in elderly NDMM patients. Responses were rapid and deep, and showed improvement over time. Forty-nine percent of patients achieved ⩾ near-complete response (nCR) and 20% of patients achieved a stringent CR (sCR). After a median follow-up of 18 months, the 2-year PFS rate was 76%. Severe haematological adverse events (AEs) occurred in o 20% of patients and non-haematological AEs occurred in o 10% of patients, with a low (18%) rate of discontinuation. 15 Given the improved haematological safety profile of cyclophosphamide and the previous encouraging results with KCyd, 15 we conducted a phase 1/2 study to determine the maximum tolerated dose (MTD) and evaluated the safety and efficacy of once-weekly wKCyd in elderly NDMM patients. We report the safety and efficacy results of the trial herein.
PATIENTS AND METHODS Patients
Patients with symptomatic NDMM, who were aged ⩾ 65 years or ineligible for autologous transplantation were included in the study. Further eligibility criteria included measurable disease, Eastern Cooperative Oncology Group performance status ⩽ 2, creatinine clearance ⩾ 15 ml/ min, platelet count ⩾ 50 × 10 9 /l (⩾30 × 10 9 /l if myeloma involvement in the bone marrow was 450%) and absolute neutrophil count of ⩾ 1 × 10 9 /l without the use of growth factors. Patients were excluded from the study if they had non-secretory MM (unless serum-free light chains were present and the ratio was abnormal, namely o 0.26 or 41.65), grade 42 peripheral neuropathy and active infection. 16 In addition, per protocol, patients had to undergo echocardiogram (ECHO) and electrocardiogram, and were excluded from the trial if they had left ventricular ejection fraction o40% evaluated with two-dimensional transthoracic ECHO (or Multigated Acquisition Scan if ECHO was not available), myocardial infarction or unstable angina ⩽ 4 months before enrolment, uncontrolled angina, history of severe coronary artery disease, or electrocardiographic evidence of acute ischaemia or grade 3 conduction system abnormalities unless the subject had a pacemaker, uncontrolled hypertension, uncontrolled congestive heart failure or uncontrolled diabetes within 14 days before enrolment.
All patients gave written informed consent to participate in the study, which had been approved by the institutional ethics committees. The study was conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. The study is registered at Clinicaltrials.gov NCTNCT01857115.
Study design and treatment
This multicentre, non-randomized, open-label, dose-escalation phase 1/2 study determined the safety and efficacy of wKCyd in NDMM patients. The primary objective of the phase 1 portion was to determine the MTD of once-weekly carfilzomib with cyclophosphamide and dexamethasone. The primary objective of the phase 2 portion was to determine the overall response rate. Secondary endpoints included response rates, PFS, time to progression, duration of response, OS, time to next therapy, subgroup analyses of prognostic factors, the evaluation of the effect of maintenance on PFS and OS, and the relationship between responses and PFS in responding and non-responding patients.
All Figure S1) . Treatment was given every 28 days for nine cycles. Patients then received maintenance therapy with carfilzomib at the MTD on days 1, 15 every 28 days until progression or intolerance. Intravenous hydration (250 ml) before and after dose administration was given during cycle 1 and at the investigator's discretion thereafter.
Any toxicity requiring a dose reduction within cycle 1, inability to receive day-1 dose of cycle 2 due to drug-related toxicity persisting from cycle 1, including cardiovascular events, represents a dose-limiting toxicity (DLT). In addition, regardless of dose modification or treatment delay, among haematologic toxicities, grade 4 neutropenia or thrombocytopenia lasting for ⩾ 7 days, febrile neutropenia, grade 3-4 thrombocytopenia associated with bleeding are considered DLTs. Among non-haematologic toxicities, grade ⩾ 3 nausea, vomiting or diarrhoea despite maximal antiemetic/ antidiarrhoeal therapy, grade 4 fatigue lasting for ⩾ 7 days are DLTs, as well as the first occurrence of grade ⩾ 2 neuropathy with pain in the first treatment cycle.
Assessment
For all patients receiving at ⩾ 1 dose of any study drug, toxicity was assessed according to the National Cancer Institute Common Terminology Criteria, version 4.0. 17 Response was assessed according to the International Myeloma Working Group criteria 18 with the addition of nCR, defined as the absence of monoclonal component in the serum and/or urine with immunofixation positive. The response assessments were undertaken at the beginning of each treatment cycle (Supplementary Figure S1 ) during induction and every three cycles during maintenance. Fluorescence in situ hybridization was used to detect t(4:14), t(11:14), t(14;16), del13 and del (17p). Bone marrow samples were collected at study entry and investigations were performed at one central laboratory. For the present analysis, the cutoff value of 60% for the proportion of plasma cells with del (17p) was used, according to the recommendation from the International Myeloma Workshop Consensus panel 2. 19 
Statistical analysis
For the sample size of the phase 1 portion of the study, each wKCyd dose level cohort could have a minimum of three patients and a maximum of six patients. Therefore, a maximum of 18 patients could be recruited in the phase 1. The sample size of the phase 2 portion of the study was estimated according two-stage Simon optimal design, with early stopping rules in case of efficacy lower than a predefined uninteresting response rate. We assumed an overall response rate p0 of 0.40, under which further study of the wKCyd combination would not be justified, and an overall response rate p1 of 0.60, which could justify additional investigation of this combination. Probability of type I (α) error was set to be 0.05 and type II (β) error 0.20. In the first stage of phase 2, 16 patients had to be accrued. If seven or less responses had been observed, the trial would have been stopped for futility. Otherwise, 30 additional patients would have been accrued in the second stage: if 23 or fewer responses had been observed by the end of this stage, no further investigation would have been warranted. With this design, the expected number of enrolled patients was 46 and the probability of early termination was 71.6%. Assuming~10% of patients lost to follow-up, an adequate sample size was 53 patients.
Response rates and safety were analysed in patients who received ⩾ 1 dose of study treatment. Time-to-event endpoints were determined using the intent-to-treat population. The Kaplan-Meier product limit method was used to estimate survivorship functions for time-to-event endpoints. Cox proportional hazards regression was used to assess the effects of demographic and prognostic variables on relative treatment differences. Continuous and categorical data were summarized using descriptive statistics. SAS System version 8.2 system (SAS Institute Inc., Cary, NC, USA) was used.
Role of the funding source
The study was sponsored by Hovon Foundation and co-sponsored in Italy by Fo.Ne.Sa. Onlus and it was supported by funding from Onyx Pharmaceuticals, Inc. (South San Francisco, CA, USA) first and Amgen (Thousand Oaks, CA, USA) afterwards. The funders had no role in the collection, analysis or interpretation of data. All authors had full access to Phase 1/2 study of wKCyd S Bringhen et al all data in the study and had final responsibility for the decision to submit for publication.
RESULTS

Patients
Patients were enrolled from 10 April 2013 to 24 August 2015, in 8 centres in Italy. Twelve patients were enrolled in the phase 1 doseescalation portion of the study and 51 patients were enrolled in the phase 2 portion. A total of 54 patients were treated at the recommended phase 2 dose (RP2D) and could be assessed for efficacy and safety (Supplementary Figure S2) . Baseline demographics and disease characteristics for patients enrolled in all study phases are listed in Table 1 Table S1 ).
Efficacy of RP2D
Overall, among patients receiving carfilzomib at the MTD, 46/54 (85%) patients had at least a partial response (⩾ PR), 36/54 (66%) patients had at least a very good PR ( ⩾ VGPR) and 16/54 (30%) patients had at least a ⩾ nCR (Supplementary Table S1 ). Depth of response increased with prolonged treatment. At the end of four cycles, 43/48 (90%) patients achieved ⩾ PR, including 18/48 (38%) patients with ⩾ nCR. Among patients who completed nine cycles of treatment, 37/40 (93%) had ⩾ PR and 18/40 (44%) had ⩾ nCR. Among patients who received maintenance, 39/40 (98%) had ⩾ PR and 22/40 (54%) had ⩾ nCR, including 12/40 (29%) CR and 4/40 (10%) sCR ( Table 2 ). The median time to achieve PR was 2.4 months, but median time to sCR was 12 months and~50% of patients with CR achieved CR during maintenance (Figure 1 ). The quality of response impacted on long-term outcome. At 2 years, the proportion of patients alive and in remission was 100% in patients who achieved sCR, 60% in those who achieved VGPR or CR and 44% in those who achieved PR. Response rates were generally similar across patient groups according to International Staging System stage and chromosomal profile ( Table 2) .
After a median follow-up of 19.7 months (interquartile range 14.3-28.3), the 2-year PFS and OS rates were 53.2% and 81%, respectively (Figure 2 ). The risk of progression was slightly higher in patients with International Staging System III (hazard ratio 2.46; 95% confidence interval 0·99-6.1, P = 0.05) but not with high-risk chromosomal abnormalities. The 2-year PFS was 68% in high-risk patients and 53% in standard-risk ones (hazard ratio 0.45; 95% confidence interval 0.12-1.7, P = 0.24).
Safety of RP2D During induction, the most common toxicities of any grade were anaemia (39%), thrombocytopenia (33%), neutropenia (31%), Per-protocol analysis: only patients who received at least 2, 4, 6 and 9 cycles, and maintenance were evaluated.
Phase 1/2 study of wKCyd S Bringhen et al cardiovascular events (24%), nausea/vomiting (19%), fever (13%), infections (13%) and fatigue (9%). Grade 3-5 haematological toxicities included neutropenia (22%), thrombocytopenia (7%) and anaemia (2%). The most common grade 3-5 non-haematological AEs were cardiovascular events (9%), metabolic events (6%), infections (7%) and renal events (4%) ( Table 3) .
Treatment-emergent serious AEs occurred during induction in 14 patients (26%) and included four renal failures, eight cardiac events (three heart failures, three pulmonary oedemas, one sudden death and one hypertension), four infections (two pneumonias, one sepsis and one upper respiratory tract), one reversible posterior leukoencephalopathy, one hyponatremia, one respiratory failure, one adult respiratory distress syndrome and one pulmonary thromboembolism. A limited number of patients required dose modification during induction: 12 patients (22%) discontinued treatment owing to AEs and 5 patients (9%) required carfilzomib dose reductions (Supplementary Table S2 ).
A total of six patients died during induction; causes of death were disease progression (two patients) and AEs (pulmonary thromboembolism, acute respiratory failure, pneumonia and sudden death in one patient each) (Supplementary Table S2 ).
During maintenance, the most common toxicities of any grade were anaemia (8%), thrombocytopenia (20%), neutropenia (5%), fever (15%), hypertension (15%) and nausea/vomiting (10%). No grade 3-5 haematological toxicities were reported. Grade 3-5 non-haematological AEs were rare and occurred in o5% of patients, with the exception of hypertension, which was reported in 10% and cardiovascular AEs in 5% (one heart failure and one myocardial infarction). Treatment-emergent serious AEs occurred during maintenance in three patients and included urinary tract infection, heart failure and myocardial infarction.
DISCUSSION
This trial is the first to investigate carfilzomib on a once-weekly dosing schedule with cyclophosphamide and dexamethasone as part of frontline therapy in patients over 65 years of age with symptomatic MM. The MTD of weekly carfilzomib incorporated into the wKCyd regimen was found to be 70 mg/m 2 . Severe haematological AEs occurred in 26% of patients and nonhaematological AEs occurred in 35% of patients, with 22% of discontinuation.
These results compare favourably with other studies assessing twice weekly carfilzomib-based regimens as frontline therapy in elderly patients ineligible for autologous transplantation. The rate of haematological and non-haematological AEs were similar to, or lower than, those reported in our previous study with twice weekly carfilzomib at the dose of 36 mg/m 2 in combination with cyclophosphamide and dexamethasone. 15 Myelosuppression induced by cyclophosphamide was lower than the one observed with melphalan in combination with twice-weekly carfilzomib and prednisone, which led to grade 3-4 neutropenia in 38% of patients and grade 3-4 thrombocytopenia in 28%. 20 This lower myelosuppression translated in a lower incidence of infections (13% in our trial versus 53% in the carfilzomib and prednisone trial). 20 The recent results of CLARION study comparing carfilzomib and prednisone with VMP showed no difference in PFS between the two regimens. 21 This is probably due to a higher incidence of severe AEs and of toxic deaths in patients receiving carfilzomib and prednisone. Cyclophosphamide may therefore represent a valid, less toxic alternative to melphalan for elderly patients with NDMM.
This effect has been observed even in the context of bortezomib-based treatments with higher rates of grade 3 neutropenia (40% vs 30%, respectively) and thrombocytopenia (37% vs 12%, respectively) in the VMP therapeutic scheme compared with bortezomib-cyclophosphamidedexamethasone. 7, 22 Regarding the choice of the optimal upfront proteasome inhibitor in elderly NDMM patients, a direct comparison between wKCyd regimen and similar bortezomib-based regimens is difficult because of the heterogeneity of involved studies. However, wKCyd compared favourably with VMP (⩾ VGPR rate 69% vs 41%) and bortezomib-cyclophosphamide-dexamethasone ( ⩾ VGPR rate 69% vs 41%) in terms of efficacy. 7, 22 As for safety, grade 3 peripheral neuropathy rate was 15% with the abovementioned bortezomib-based regimens, whereas it was not an issue in the current trial. However, AEs resulting in discontinuation of therapy were slightly more frequent with the wKCyd regimen than with VMP and bortezomib-cyclophosphamide-dexamethasone (22% vs 15% vs 12%, respectively).
During induction, cardiovascular events occurred in 24% of patients, including 9% of grade 3-5 AEs, although all patients had a baseline left ventricular ejection fraction ⩾55%. Among severe cardiac AEs, the most frequent were heart failure and pulmonary oedema. The rate of hypertension was 11% during induction, limited to grade 1-2, but it increased to 15% during maintenance, including 10% of grade 3-4. In the present study, cardiovascular toxicity was higher compared with our previous KCyD trial with twice-weekly carfilzomb at 36 mg/m 2 , but similar to that reported in more recent trials in NDMM setting, such as the CLARION study, 21 as well as in relapsed/refractory multiple myeloma patients, such as the ASPIRE and the ENDEAVOR trials. 12, 23 The effect of proteasome inhibition on cardiovascular system has only recently begun to be understood. Yet, there is some evidence, suggesting that the ubiquitine-proteasome system must be considered a modulator of endothelial (dys)-function by interaction with several essential regulatory pathways and regulation of endothelial-dependent contracting and vasodilation factors. Endothelial dysfunction is accompanied by deterioration in this balance, with progressive reduction in vasodilation factors and with an increase in vasoconstriction mediators. Available data suggest that short-term, non-toxic proteasome inhibitors may be beneficial, whereas higher proteasome-inhibitor doses and longterm administration are associated with more disadvantageous effects in the vasculature. 24 These data suggested a time-and dose-dependent effect of carfilzomib. For patients, especially elderly ones, candidate to treatment with carfilzomib, a careful assessment before starting treatment and monitoring during treatment is suggested. Before starting treatment, clinicians should evaluate medical history-to determine previous cardiac events and cardiovascular risk factors-and perform a physical examination to assess blood pressure (BP), valvular heart disease and signs of heart failure. A 12-lead electrocardiogram is essential to detect possible markers of structural heart disease including the left ventricular damage/dysfunction, arrhythmias, evidence of previous myocardial infarction or evidence of the left ventricular hypertrophy. The ENDEAVOR substudy found limited utility for serial screening with ECHO to mitigate cardiac risk. 25 Nevertheless, four recent guidelines suggest that a baseline ECHO is useful to measure the left ventricular ejection fraction before starting treatment. [26] [27] [28] [29] Finally, a 24 h BP monitoring (ambulatory BP monitoring) or home BP monitoring for at least 7-14 days is needed to look for unknown or borderline or uncontrolled We showed that treatment with wKCyd was highly effective in elderly NDMM patients. Responses were rapid and deep, and improved over time. During induction, 66% of patients achieved ⩾ VGPR, including 30% nCR and 15% CR. During maintenance, 88% of patients achieved ⩾ VGPR, including 54% nCR and 29% CR. Fifty percent of CR/sCR patients achieved CR/sCR during maintenance with a mean time to CR/sCR 412 months. After a median follow-up of 19.7 months, the 2-year PFS and OS rates were 53.2% and 81%, respectively. The achievement of CR has been associated with prolonged PFS and OS, also in elderly patients. 30 In addition, maintenance therapy improves outcome, and its role has been extensively investigated. [31] [32] [33] The ideal treatment should combine high response rates and continuous therapy to prolong long-term outcome. Despite the limitations of cross-trial comparisons, the promising antitumour activity observed with weekly carfilzomib in this study was similar to-or even better than-that reported in our prior study with twice weekly carfilzomib and also to the one observed in the French phase 1/2 trial and in the CLARION trial, both with twice weekly carfilzomib plus melphalanprednisone. 20, 21 The improved results with wKCyd were probably due to the better risk/benefit profile and the continuous treatment with carfilzomib. Nevertheless, better results were seen with carfilzomib-lenalidomide-dexamethasone combination, which induced an at least nCR rate of 62-63%, including a sCR rate of 42% and a 2-year PFS rate of 92%. 34, 35 The higher CR rate observed in these patients was probably attributable to the combination of a proteasome inhibitor and an immunomodulatory agent, and to the enrolment of younger patients. Indeed, in that studies, median age was 59-60 years, with 57-58% of patients o 65 years and thus potentially transplant eligible. Of note, the combination KCyd has the advantage of a lower cost, providing good efficacy. Furthermore, as survival continues to improve in MM patients, it is essential to consider subsequent treatment options when choosing therapy at diagnosis. As KCyd regimen does not use bortezomib or lenalidomide, patients initially treated with KCyd may still receive these other agents at relapse.
No statistically significant PFS difference was observed in patients with high risk cytogenetic status compared with those with standard risk (2-year PFS 68% versus 53%, hazard ratio 0.45, P = 0.24). Although the number of patients in this subgroup analysis was limited and definitive conclusions cannot be drawn, these data are consistent with those reported in the subgroup analysis of the ASPIRE trial. This pre-planned analysis showed that carfilzomib-lenalidomide-dexamethasone in relapsed/refractory patients improved the poor prognosis associated with high-risk cytogenetics. 36 Similar results were reported in two phase 2 studies with carfilzomib-lenalidomide-dexamethasone in NDMM. 34, 35 These data, if confirmed on a larger number of patients, may have important implications regarding risk-adapted therapy.
In conclusion, our study showed that in elderly patients ineligible for transplant, the more convenient dosing schedule wKCyd was highly effective with excellent CR rates and had an acceptable toxicity.
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